olfactory receptor family 52 subfamily B member 5 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR52B5P profile across patient tissues and cancer cell-line models. OR52B5P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, OR52B5P is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, OR52B5P RNA expression shows 11,473 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, UCEC, and LSCC as cancer lineages where OR52B5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR52B5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR52B5P survival associations across molecular data types. OR52B5P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR52B5P RNA expression–survival associations across cancer types. High OR52B5P expression shows unfavorable associations in KICH, HNSC, KIRC, READ and TGCT, but favorable associations in LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for OR52B5P RNA expression.
This table summarizes OR52B5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for OR52B5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR52B5P shows lower tumor expression in UCEC, BRCA and KICH and higher tumor expression in BLCA. The UCEC box plot shows higher OR52B5P RNA expression in normal versus tumor tissue (log2 FC = −0.062, t-test p = .006).
This table shows molecular features associated with OR52B5P in patient tissues and cancer cell lines. In patient samples, OR52B5P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
